{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:49:02Z","timestamp":1789422542640,"version":"build-2803163510"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Research and Development Center, Dayanand Medical College and Hospital, Ludhiana, India","award":["DMCH\/R&D\/2021\/74"],"award-info":[{"award-number":["DMCH\/R&D\/2021\/74"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Oral corticosteroids are first-line agents to induce remission in moderately active ulcerative colitis [UC], but are associated with adverse effects. We compared the efficacy and safety of tofacitinib and prednisolone for induction of remission in moderately active UC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a single-centre, prospective, open-label, randomized, active-controlled pilot study. Eligible patients [aged \u226518 years] had moderately active UC. Participants were randomly assigned to receive either prednisolone [40 mg daily, tapered by 5 mg every week] or tofacitinib [10 mg twice daily] for 8 weeks. The primary endpoint was composite remission [defined as total Mayo clinic score \u22642, with endoscopic sub-score of 0 and faecal calprotectin &amp;lt;100 \u00b5g\/g] at 8 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy-eight patients were randomly assigned to either of the treatment groups. At week 8, the proportion of patients achieving composite remission in the tofacitinib [7\/43, 16.28%] and prednisolone groups [3\/35, 8.57%] were not significantly different (odds ratio [OR] 2.07, 95% confidence interval [CI] 0.49\u20138.70; p\u2005=\u20050.31). The time to achieve symptomatic remission [normal stool frequency with absence of rectal bleeding] was similar (10 days, interquartile range [IQR 7\u201318.75] and 10 days [IQR 5\u201312.5] for tofacitinib and prednisolone, respectively; p\u2005=\u20050.25) in the two groups. One patient each in the tofacitinib and prednisolone group discontinued treatment due to development of pulmonary tuberculosis and pustular acne, respectively. One patient receiving tofacitinib developed herpes zoster, but did not require cessation of therapy. No serious adverse events or major adverse cardiovascular events were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with moderately active UC, there was no difference in the efficacy and safety of tofacitinib and oral prednisolone for induction of remission at 8 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trail Registration<\/jats:title>\n                  <jats:p>Clinical Trials Registry of India [CTRI\/2021\/10\/037641]<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjad153","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T18:40:03Z","timestamp":1693593603000},"page":"300-307","source":"Crossref","is-referenced-by-count":30,"title":["Tofacitinib Versus Oral Prednisolone for Induction of Remission in Moderately Active Ulcerative Colitis [ORCHID]: A Prospective, Open-Label, Randomized, Pilot Study"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7163-0454","authenticated-orcid":false,"given":"Arshdeep","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College , Ludhiana, Punjab , 141001 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Midha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dayanand Medical College , Ludhiana, Punjab, 141001 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirandeep","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Dayanand Medical College , Ludhiana, Punjab, 141001 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6726-6151","authenticated-orcid":false,"given":"Ramit","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College , Ludhiana, Punjab , 141001 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmatma","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College , Ludhiana, Punjab , 141001 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramandeep","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College , Ludhiana, Punjab , 141001 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Kohli","sequence":"additional","affiliation":[{"name":"Dayanand Medical College , Ludhiana, Punjab, 141001 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avantika","family":"Chawla","sequence":"additional","affiliation":[{"name":"Dayanand Medical College , Ludhiana, Punjab, 141001 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriti","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Government Medical College and Rajindra Hospital , Patiala, 147001 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Bansal","sequence":"additional","affiliation":[{"name":"Research and Development Centre, Dayanand Medical College , Ludhiana, Punjab, 141001 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6961-6389","authenticated-orcid":false,"given":"Ajit","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dayanand Medical College , Ludhiana, Punjab , 141001 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"2024022621400885100_CIT0001","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024022621400885100_CIT0002","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2024022621400885100_CIT0003","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/s41395-018-0108-6","article-title":"Persistence with immunomodulator monotherapy use and incidence of therapeutic ineffectiveness among users of immunomodulator monotherapy in IBD","volume":"113","author":"Targownik","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2024022621400885100_CIT0004","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2024022621400885100_CIT0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12876-022-02215-y","article-title":"Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis","volume":"22","author":"Chiorean","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"2024022621400885100_CIT0006","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.dld.2021.11.009","article-title":"Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel","volume":"54","author":"Avni-Biron","year":"2022","journal-title":"Dig Liver Dis"},{"key":"2024022621400885100_CIT0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","article-title":"Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry","volume":"15","author":"Chaparro","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024022621400885100_CIT0008","doi-asserted-by":"crossref","first-page":"861","DOI":"10.14309\/ajg.0000000000002129","article-title":"REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD Research Consortium Multicenter National Cohort Study","volume":"118","author":"Ma","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2024022621400885100_CIT0009","first-page":"2106","article-title":"Positioning tofacitinib in the treatment algorithm of moderate to severe ulcerative colitis","volume":"24","author":"Danese","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2024022621400885100_CIT0010","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2024022621400885100_CIT0011","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.2010.224154","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"60","author":"Mowat","year":"2011","journal-title":"Gut"},{"key":"2024022621400885100_CIT0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5217\/ir.2020.00155","article-title":"Use of thiopurines in inflammatory bowel disease: an update","volume":"20","author":"Singh","year":"2022","journal-title":"Intest Res"},{"key":"2024022621400885100_CIT0013","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024022621400885100_CIT0014","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/jgh.15923","article-title":"Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open","volume":"37","author":"Matsuoka","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"2024022621400885100_CIT0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2024022621400885100_CIT0016","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.gastha.2022.01.005","article-title":"Lamina propria phagocyte profiling reveals targetable signaling pathways in refractory inflammatory bowel disease","volume":"1","author":"Jacobsen","year":"2022","journal-title":"Gastro Hep Adv"},{"key":"2024022621400885100_CIT0017","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024022621400885100_CIT0018","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","article-title":"American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"key":"2024022621400885100_CIT0019","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/ibd\/izaa289","article-title":"Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM marketscan\u00ae administrative claims database with tofacitinib trial data","volume":"27","author":"Curtis","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2024022621400885100_CIT0020","doi-asserted-by":"crossref","first-page":"e01066","DOI":"10.14309\/crj.0000000000001066","article-title":"Miliary tuberculosis in a patient with ulcerative colitis treated with tofacitinib","volume":"10","author":"Verma","year":"2023","journal-title":"ACG Case Reports Journal"},{"key":"2024022621400885100_CIT0021","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjad153\/51854986\/jjad153.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/2\/300\/56759587\/jjad153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/2\/300\/56759587\/jjad153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T21:49:00Z","timestamp":1708984140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/2\/300\/7258619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,9,1]]},"published-print":{"date-parts":[[2024,2,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad153","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2023,9,1]]}}}